Toronto, Ontario--(Newsfile Corp. - March 25, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Dr. Nick Smit as part of the HemoPalm biosensor development team.
Dr. Nick Smit received his Ph.D. in Analytical Chemistry from the University of Delaware and began his career at i-Stat in Princeton, New Jersey and later Ottawa, Ontario where he rose to the position of Senior Scientist.
During his time at i-Stat Nick was co-inventor of numerous patents with Steve Cozzette who leads the ChroMedX biosensor development project.
"We are very pleased to have Dr. Smit join the team. Nick brings a wealth of expertise to our company and adds to the impressive group of leading experts we have contributing to the commercialization of the HemoPalm technology" said Dr. Wayne Maddever, ChroMedX Corp., President & CEO
After leaving i-Stat, Dr. Smit has held senior executive roles at several life sciences companies. Dr. Smit's expertise includes microsensor design and manufacturing, process validation and FDA 510(k) approvals.
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
Website: www.ChroMedX.com
Facebook: facebook.com/ChroMedXcorp
Twitter: www.twitter.com/ChroMedXcorp
Contact
W. Clark Kent
Corporate Development
647-519-2646
ckent@ChroMedX.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com
The security symbol, MNLIF, is part of the OTC Grey Market, where Monarch does not provide any reports and has no obligation to do so. There are no market makers under this symbol of this security. It is not listed, traded or quoted on any U.S. stock exchange or the OTC Markets. Trades in grey market stocks are reported by broker-dealers to their Self Regulatory Organization (SRO) and the SRO distributes the trade data to market data vendors and financial websites so investors can track price and volume. Since grey market securities are not traded or quoted on an exchange or interdealer quotation system, investor's bids and offers are not collected in a central spot so market transparency is diminished and best execution of orders is difficult.
